United Therapeutics’ latest quarter saw revenue exceed Wall Street expectations, but a notable decline in operating margin and GAAP profit below consensus drove a negative market response. Management attributed revenue growth primarily to strong demand for Tyvaso, citing increased patient starts, referrals, and higher dosing levels, with no significant inventory or seasonal effects. President Michael Benkowitz highlighted, “We are stacking good months on top of good months,” confirming consistent execution by the commercial team. Management acknowledged that recent investments in sales resources and focused messaging have begun to expand reach and deepen physician engagement in core therapeutic areas.
Is now the time to buy UTHR? Find out in our full research report (it’s free for active Edge members).
United Therapeutics (UTHR) Q3 2026 highlights:
- Revenue $832.5 million vs S&P analysts’ estimates of $782.6 million (4.1% year-on-year growth, 6.4% beat)
- Adjusted EPS $5.71 vs S&P analysts’ expectations of $6.34 (10% miss)
- Operating margin 37%, down from 48.6% in the same quarter last year
- Market capitalization $24.09 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from United Therapeutics’s Q3 earnings call
-
Joseph Thome (TD Cowen) asked about the expected impact of the PH-ILD label removal for YUTREPIA on patient switching. President Michael Benkowitz stated there is no requirement for existing patients to switch, and future growth will focus on new starts and physician education.
-
Olivia Brayer (Cantor) inquired whether the sales force expansion and court settlement were already driving increased Tyvaso starts. Benkowitz clarified that while referral trends improved in October, the full impact of these initiatives is expected in the coming quarters. Pat Poisson, EVP, confirmed the soft mist inhaler NDA submission is now planned for next year.
-
Ash Verma (UBS) asked about the regulatory risk tied to the ralinepag API manufacturer’s compliance status. EVP Pat Poisson explained that remediation efforts are underway, and contingency supply plans are being developed in parallel to avoid approval delays.
-
Roger Song (Jefferies) questioned the development path for the triple oral pill after feedback from the FDA. Poisson said the company is evaluating alternate options and timelines, with further updates expected as discussions with regulators continue.
-
Roanna Ruiz (Leerink Partners) sought clarity on the main drivers behind Tyvaso’s recent performance. Benkowitz emphasized that growth was primarily from underlying demand and higher dosing, not from inventory or seasonal effects, and the sales force expansion’s impact should accelerate going forward.
Catalysts in upcoming quarters
In the coming quarters, the StockStory team will be watching (1) progress on regulatory filings and approvals for nebulized Tyvaso in IPF and ralinepag in PAH, (2) evidence that the expanded sales force translates into sustained prescription growth and deeper physician engagement, and (3) resolution of manufacturing and compliance issues that could impact key product launches. Ongoing monitoring of competitor activity and the pace of new patient identification will also be important for tracking the company’s trajectory.
United Therapeutics currently trades at $565.21, down from $601.32 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
High-quality stocks for all market conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
